The Chemours Company (CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions (“TSS”), Titanium Technologies (“TT”), and Advanced Performance Materials (“APM”), today announced its financial results for the fourth quarter and full year 2024.
Key Fourth Quarter 2024 Results & Highlights
- Net Sales of $1.4 billion, in line with the corresponding prior-year quarter, with TSS achieving record fourth quarter Net Sales, driven by year-over-year growth of 23% in Opteon™ Refrigerants
- Net Loss attributable to Chemours of $8 million, or $0.05 per diluted share, compared with a Net Loss attributable to Chemours of $18 million, or $0.12 per diluted share, in the corresponding prior-year quarter
- Adjusted Net Income1 of $16 million, or $0.11 per diluted share, compared with $46 million, or $0.31 per diluted share, in the corresponding prior-year quarter
- Adjusted EBITDA1,2 of $179 million compared to $176 million in the corresponding prior-year quarter
- Cash returned to shareholders through dividends of $36 million in the quarter
Key Full Year 2024 Results & Highlights
- Net Sales of $5.8 billion compared to $6.1 billion in the prior year
- Net Income attributable to Chemours of $86 million, or $0.57 per diluted share, compared with a Net Loss attributable to Chemours of $238 million, or $1.60 per diluted share, in the prior year3
- Adjusted Net Income1 of $182 million, or $1.21 per diluted share, compared to $425 million, or $2.82 per diluted share, in the prior year3
- Adjusted EBITDA1,2 of $786 million compared to $1.0 billion in the prior year
- Cash returned to shareholders through dividends of $148 million in the year
- Established new executive leadership team and announced Chemours’ Pathway to Thrive strategy to drive shareholder value
- Announced PCC Group’s plans to build a chlor-alkali facility at Chemours’ TiO2 plant in DeLisle, Mississippi and completed our planned Opteon™ YF expansion at Corpus Christi, Texas
- Fully remediated all four material weaknesses in internal control previously identified in the 2023 Form 10-K
Full Year 2025 Outlook4
- Adjusted EBITDA between $825 million and $975 million
- Capital expenditures between $250 million to $300 million
How well do narratives help inform your perspective?
Disclaimer
The user WaneInvestmentHouse has a position in NYSE:CC. Simply Wall St has no position in any of the companies mentioned. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
WA
Consensus Narrative from 10 Analysts
New Investments In High-Purity Resins And Opteon Refrigerants Will Improve Future Operational Efficiency
Key Takeaways Chemours aims to boost operational efficiency and net margins through cost savings and strategic expansion, including a significant increase in production capacity. Investments in high-growth areas and products like Opteon refrigerants and high-purity resins are expected to drive revenue growth and strengthen market position.
View narrativeUS$23.80
FV
26.6% undervalued intrinsic discount4.82%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
23 days ago author updated this narrative
